Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 78 for:    vismodegib

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01944943
Recruitment Status : Terminated (lack of efficacy)
First Posted : September 18, 2013
Last Update Posted : March 13, 2017
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).

Condition or disease Intervention/treatment Phase
Diffuse Large B-cell Lymphoma Indolent Non-hodgkin Lymphoma Primary Central Nervous System Lymphoma Chronic Lymphocytic Leukemia Drug: Vismodegib Phase 2

Detailed Description:

This is a multicenter open-label phase II study.

Primary objective:

To evaluate the efficacy of vismodegib in patients with relapsed/refractory B-cell lymphoma and CLL as measured by the best overall response rate (ORR) during the treatment period.

Secondary objectives:

  • To evaluate the tolerability and the safety of vismodegib in patients with relapsed/refractory B-cell lymphoma and CLL
  • To evaluate the efficacy of vismodegib in patients with relapsed/refractory B-cell lymphoma and CLL by measuring the overall (OR) and complete response (CR) rate during the study period, the maximum tumor shrinkage, the duration of response, the progression-free survival (PFS) and the overall survival (OS).
  • To examine the expression of GLI-1 and other Hedgehog (Hh) signalling components in the tumor specimens before and during treatment with vismodegib and corresponding efficacy in patients.

    44 patients will be included in the study equally distributed into 4 cohorts according to their histological subtype:

  • Cohort 1: 11 patients with Diffuse large B-cell lymphomas (DLBCL)
  • Cohort 2: 11 patients with "indolent" lymphomas (iNHL): Follicular (FL), mantle cell (MCL) and marginal zone lymphoma (MZL) lymphoplasmacytic lymphoma (LPL)/ Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL)
  • Cohort 3: 11 patients with Primary central nervous system lymphomas (PCNSL)
  • Cohort 4: 11 patients with Chronic lymphocytic leukemia (CLL).

After 28 days screening period (Baseline), each patient will be treated by Vismodegib 150 mg per os during for a maximum of 12 months until disease progression, unacceptable toxicities, patient consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor.

Tumour assessment (clinical examination, laboratory tests, abdominal and chest CT scan (for PCNSL only at baseline), +/- PET scan for DLBCL, +/- brain MRI and CSF examination and ophthalmic examination for PCNSL, +/- bone marrow examination (except for PCNSL) will be performed at baseline, and then every 2 months during the first 6 months of treatment, and every 3 months thereafter until disease progression or up to 6 months after study treatment stop.

Response to treatment will be assessed also by Pharmacodynamic study in tumor samples by immunohistochimic and qPCR analysis at baseline and after one month of treatment with vismodegib.

Pharmacokinetic studies (before and after 1 month of treatment) will also be performed.

After study treatment discontinuation, the patients will be followed up every 3 months until disease progression or up to 6 months (after 1 year treatement).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Study Start Date : February 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : October 2014


Arm Intervention/treatment
Experimental: Vismodegib
Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
Drug: Vismodegib
150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
Other Name: GDC-0449, ERIVEDGE®




Primary Outcome Measures :
  1. The best overall response rate(ORR) [ Time Frame: 12 months ]

    ORR will be measured by the best overall response (complete response (CR), uncofirmed complete response (CRu) or partial response (PR)) recorded during whole treatment period from the baseline until the end of treatment.

    ORR will be assessed according to Cheson 1999 for DLBCL and iNHL, according to Abey 2005 (IPCG response criteria) for PCNSL and to Hallek 2008 (IWCLL response criteria) for CLL.



Secondary Outcome Measures :
  1. Overall Response rate [ Time Frame: 2, 4, 6, 9, and 12 months ]
    Overall response rate will be evaluated as ORR, CR, CRu, PR, stable disease (SD) and progressive disease (PD) after 2, 4, 6, 9, and 12 months of treatment and every 3 months for 6 months after treatment discontinuation, until disease progression.

  2. Progression Free Survival (PFS) [ Time Frame: Up to 3 year ]
    Progression-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse or death from any cause. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.

  3. Response Duration [ Time Frame: Up to 3 year ]
    Duration of response will be measured from the time of attainment of first CR, CRu or PR to the date of first documented disease progression, relapse or death from any cause. Subjects with no documented progression after CR, CRu or PR will be censored at the last tumor assessment date.

  4. Overall survival [ Time Frame: Up to 3 year ]
    Overall survival will be measured from the date of inclusion to the date of death from any cause. Alive patients will be censored at their last date known to be alive.

  5. Correlation between Hedgehog (Hh) signaling in the tumor and the efficacy of Vismodegib [ Time Frame: At baseline and at 28 days (+/- 7 days) ]

    Hh signaling cascade will be evaluated in tumors at baseline and at the end of cycle 1 (at Day 28 +/- 7 days) in order to:

    • Study pharmacodynamic of the drug (extinction of Hh signaling under treatment with Vismodegib)
    • Search for correlation between Hh signaling and clinical response to Vismodegib

  6. Safety endpoints [ Time Frame: Up to 2 year ]
    Description of all adverse events (AEs), laboratory data, vital signs and ECOG performance status, performed by cycle/visit and for the entire study.

  7. Overall Response rate [ Time Frame: 12 months ]
    Overall response will also be assessed using the Cheson 2007 criteria in patients with DLBCL. Patient without response assessment (due to whatever reason) will be considered as non-responder.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of B-cell lymphoma (DLBCL, MCL, FL, MZL, LPL/WM, SLL or PCNSL) or CLL (Matutes score ≥4) requiring treatment that is recurrent after at least one prior therapy for which no potentially curative therapy nor better treatment option is available. Specifically, the patient should have received all treatments considered to be standards of care, including stem cell transplantation (when appropriate, if patient eligible), and agents known to have significant clinical efficacy in their disease.Patient must be eligible for tumor biopsy. Biopsy at relapse is mandatory for all patients except for PCNSL (optional) and should provide enough tumor tissue for biological tests (paraffin-embedded and frozen or RNAlater-conserved tissue).
  • Age 18 and older
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
  • Signed inform consent
  • Life expectancy ≥ 3 months
  • Patients who have received up to a maximum of 4 lines of treatment (including radiotherapy)
  • Patients must have recovered from all toxicities related to prior treatments to ≤ grade 1.
  • Adequate Laboratory Parameters (unless abnormalities are related to underlying disease) within 28 days prior to signing informed consent, including:

    • Absolute neutrophil count (ANC) ≥ 1000/μL
    • Platelet ≥ 75,000/μL
    • Hemoglobin > 8.5 g/dL
    • Total bilirubin ≤ 1.5 x upper limit of normal (UNL)
    • Hepatic enzymes (AST, ALT) ≤ 3 x institutional ULN
  • Measurable disease:

    • Cohort 1 and 2 (DLBCL and iNHL): Bi-dimensionally measurable disease at CT scan with at least 2cm in their longest diameter.
    • Cohort 3 (PCNSL): Measurable PCNSL on MRI with gadolinium enhancement (no minimal size) or, for intraocular lymphoma (IOL), measurable disease at fundoscopic examination with elevated level of IL10 (>10 pg/ml) in the acqueous humor.
    • Cohort 4 (CLL): Measurable disease assessable in the blood (lymphocytosis, cytopenia) and/or by imaging (bi-dimensionally measurable disease at CT scan with at least 2cm in their longest diameter)
  • Patient must be able to take oral medication
  • Females of childbearing potential (FCBP) must :

    • have a negative pregnancy test (serum or urine, sensitivity < or = 25IU HCG/L) within 96 hours prior to starting study drug administration.
    • Agree to use two reliable forms of contraception or to practice complete abstinence from heterosexual contact during whole treatment period and up to 7 months after discontinuation of study drug treatment
  • Male patients must agree :

    • to use a condom with female of childbearing potential or to practice complete abstinence during whole treatment period and up to 7 months after discontinuation of study drug treatment.
    • To abstain from donating semen during whole treatment period and up to 7 months after discontinuation of study drug treatment
  • For all patients receiving vismodegib (GDC-0449):

    • To agree to abstain from donating blood during the whole study and for at least 7 months after discontinuation of study drug treatment
    • To agree not to share the study medication with another person

Exclusion Criteria:

  • Pregnant or breastfeeding lactating females.
  • For CLL patients, clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as judged by the treating physician
  • Concomitant anti-tumor therapy (e.g., chemotherapy, corticosteroids, other targeted therapy, radiation therapy). Corticosteroids may be authorized for PCNSL only during maximum 3 weeks (before and/or at the beginning of treatment with vismodegib) at a maximum dose of 1mg/kg of prednisone or equivalent.
  • Use of any standard or experimental anti-cancer drug therapy within 28 days prior to the study drug therapy (Day 1).
  • Patients with severe renal failure (creatinine clearance < 30 ml/min according to Cockcroft & Gault formula) and/or undergoing dialysis.

Note: Patients with moderate renal insufficiency (i.e. creatinine clearance ≥ 30 ml/min) may be included.

  • Uncontrolled and/or unstable concomitant disease such as infection requiring treatment with intravenous antibiotics.
  • HIV positive serology
  • Active hepatitis B or C
  • History of other disease, metabolic dysfunction, physical examination, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the study results or to expose the patient to high risk from treatment complications.
  • Patients unable to comply with the protocol requirements according to the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01944943


Locations
Layout table for location information
France
Hôpital Henri MONDOR
Creteil, France, 94010
CHU Dijon _ Hôpital d'Enfants
Dijon, France, 21000
CHRU de Lille _ Hôpital Huriez
Lille, France, 59800
CHU de Nantes _ Hôtel Dieu
Nantes, France, 44093
Hôpital Saint-Louis
Paris, France, 75475
CHU Haut Lévèque
Pessac, France, 33604
CH Lyon Sud
Pierre-Bénite, France, 69495
CHU Pontchaillou
Rennes, France, 35003
Centre Henri Becquerel
Rouen, France, 76038
Hôpital René Huguenin _ Institut Curie
Saint-Cloud, France, 92210
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Roche Pharma AG
Investigators
Layout table for investigator information
Principal Investigator: Roch HOUOT, MD

Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT01944943     History of Changes
Other Study ID Numbers: VISMOLY
First Posted: September 18, 2013    Key Record Dates
Last Update Posted: March 13, 2017
Last Verified: March 2017

Keywords provided by The Lymphoma Academic Research Organisation:
refractory/relapsed
diffuse large B-cell lymphoma
indolent non-hodgkin lymphoma
Primary central nervous system lymphoma
chronic lymphocytic leukemia

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell